论文部分内容阅读
目的观察多西他赛联合替吉奥胶囊治疗晚期食管癌的临床疗效及安全性。方法选择医院2014年1月-2016年5月收治住院治疗的初治晚期食管癌患者50例,随机分为观察组和对照组各25例。观察组患者接受多西他赛联合替吉奥胶囊治疗,对照组患者接受多西他赛联合顺铂治疗,观察2组患者的近期疗效、肿瘤进展时间(TTP)及不良反应发生情况。结果经2周期化疗后观察组临床总缓解率为60.00%高于对照组的48.00%,疾病控制率为72.00%略高于对照组的64.00%,2组临床总缓解率及疾病控制率无明显统计学差异(P>0.05)。对2组患者均进行随访,观察组TTP为(6.78±1.34)个月,对照组TTP为(6.81±1.27)个月,2组比较差异无明显统计学意义(t=0.017,P=0.986)。治疗前观察组有白细胞值略低于正常2例,肝功能转氨酶轻度异常2例,尿素氮轻度升高2例,轻度腹泻1例;对照组有白细胞值略低于正常3例,肝功能转氨酶轻度异常3例,尿素氮轻度升高1例,观察组患者的骨髓抑制及胃肠道反应发生率低于对照组,差异有统计学意义(P<0.05)。治疗后2组手足综合征、脱发发生率比较差异无统计学意义(P>0.05)。结论多西他赛联合替吉奥相比多西他赛联合顺铂治疗晚期食管癌疗效相当,不良反应可耐受,无明显进食梗阻,可口服药物治疗的晚期食管癌患者具有实施价值。
Objective To observe the clinical efficacy and safety of docetaxel in combination with tioguan capsule in the treatment of advanced esophageal cancer. Methods Fifty patients with newly diagnosed advanced esophageal cancer hospitalized from January 2014 to May 2016 in our hospital were randomly divided into observation group (25 cases) and control group (25 cases). Patients in the observation group received docetaxel combined with tioguan capsule, and patients in the control group received docetaxel combined with cisplatin. The short-term efficacy, tumor progression time (TTP) and adverse reactions of the two groups were observed. Results After 2 cycles of chemotherapy, the total clinical remission rate was 60.00% in the observation group and 48.00% in the control group. The disease control rate was 72.00%, which was slightly higher than 64.00% in the control group. There was no significant difference between the two groups in clinical remission rate and disease control rate Statistical difference (P> 0.05). TTP was (6.78 ± 1.34) months in the observation group and (6.81 ± 1.27) months in the control group. There was no significant difference between the two groups (t = 0.017, P = 0.986) . In the observation group before treatment, the white blood cell count was slightly lower than normal in 2 cases, slight abnormal liver function transaminase in 2 cases, slight increase in urea nitrogen in 2 cases and mild diarrhea in 1 case. In the control group, the white blood cell count was slightly lower than normal in 3 cases, There were 3 cases with slight abnormal liver function transaminase and 1 case slight increase of urea nitrogen. The incidence of bone marrow suppression and gastrointestinal reaction in the observation group was lower than that in the control group (P <0.05). There was no significant difference in the incidence of hand-foot syndrome and hair loss after treatment in both groups (P> 0.05). Conclusions Docetaxel combined with tegaserod is more effective than docetaxel plus cisplatin in the treatment of advanced esophageal cancer. Adverse reactions can be tolerated without docetaxel, and patients with advanced esophageal cancer who can be treated with oral drugs have practical value.